Mycobacterium Tuberculosis Isoniazid Resistance Detection Kit (PCR-Melting Curve Method) CapitalBio

Features

• Rapid: The whole workflow takes only 2.5 h;

• Sensitive: The LOD is as low as 800 CFU/ml with the content of isoniazid-resistance strain≥30%;

• Simple: Compatible with DxLab-32A Automated Nucleic Acid Purification and Real Time PCR System, enabling a sample in-report out workflow.

Test Method

This kit is based on PCR-melting curve technology

Sample Types

Sputum

Clinical Significance

• Early detection of INH resistance tuberculosis (TB) to reduce the spread of drug-resistant tuberculosis.

• Administer precise medications to INH resistance TB patients to effectively avoid the abuse of anti-tuberculosis drugs.

• Shorten tuberculosis treatment duration, and reduce mortality rate and medical cost.

Order Information

Background Information

Isoniazid (INH) is an important first-line anti-Tuberculosis (TB) agent because of its potent early bactericidal activity. Generally, “INH-resistant” TB refers to strain with resistance to INH and susceptibility to rifampicin (RIF) confirmed in vitro, regardless of concurrent resistance to other anti-TB drugs. “INH mono-resistance” TB refer to resistance to a single first-line drug such as INH, and susceptibility to any other anti-TB drugs. However, resistance to INH, alone or in combination with other drugs, is now one of the most common types of resistance to anti-TB drugs. Global data showed INH resistance without concurrent RIF resistance accounted for 7.1% in new TB cases and 7.9% in previously treated TB cases. Resistance to INH is usually due to a mutation in katG or inhA, and is less commonly due to mutations in other genes, such as the ahpC32 gene.